Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Uncontrolled Phase II Study Evaluating the Efficacy and Safety of Intravenous BAY59-8862 in Patients With Taxane-Resistant Metastatic Breast Cancer

NCT00044525 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00044525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00044525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Uncontrolled Phase II Study Evaluating the Efficacy and Safety of Intravenous BAY59-8862 in Patients With Taxane-Resistant Metastatic Breast Cancer
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2002
Completion date
February 29, 2004
Enrollment
82 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastatic, breast neoplasms